OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo

Video

In this video, Dr. Arman Rahman explains how the OncoMasTR protein assay may help women with breast cancer avoid unnecessary chemotherapy.

In this video, Dr. Arman Rahman explains how the OncoMasTR protein assay may help women with breast cancer avoid unnecessary chemotherapy.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content